SS Innovations, a pioneer in advanced surgical robotics, has made significant strides in the healthcare industry with the launch of the SSI Mantra 3, India’s first successful human telesurgery trial, and the addition of Dr. Fredric Moll to its leadership team.

Launch of SSI Mantra 3: The Next Generation in Robotic Surgery
SS Innovations has unveiled the SSI Mantra 3, the latest evolution in its line of surgical robotic systems. This cutting-edge technology boasts five slimmer robotic arms and an immersive 3D HD headset, providing surgeons with unmatched optical clarity and precision. Additionally, the system features a 3D 4K vision cart that enhances the entire surgical team’s ability to perform complex procedures with heightened control and accuracy.
The SSI Mantra 3 is designed to improve patient outcomes through minimally invasive surgeries, which result in less pain, reduced scarring, faster recovery times, and shorter hospital stays. Priced competitively, it aims to make advanced robotic surgery accessible to a broader range of healthcare institutions globally, underscoring SS Innovations’ commitment to affordable healthcare innovation.

Historic Milestone: India’s First Human Telesurgery Trial
In a groundbreaking achievement, SS Innovations has successfully conducted India’s first human telesurgery trial using the SSI Mantra Surgical Robot. This landmark procedure involved a robotic cholecystectomy performed over a 5-kilometer distance between the World Laparoscopy Hospital and SS Innovations’ headquarters, utilizing Airtel’s fiberoptic network with no perceptible delay. This trial marks a significant leap in surgical robotics, demonstrating the potential for providing high-quality healthcare to remote areas and aligning with the Make in India initiative.

Dr. Fredric Moll Joins SS Innovations
In a notable development, Dr. Fredric Moll, widely regarded as the father of surgical robotics and the visionary founder of Intuitive Surgical, has joined SS Innovations as a Board Member and Vice Chairman. Dr. Moll’s extensive experience and pioneering contributions to the field of robotic surgery will be instrumental in guiding SS Innovations’ strategic direction and technological advancements.

Quotes from Industry Leaders:

  • Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations: “Today marks a significant moment in our journey towards revolutionizing healthcare. With the launch of SSI Mantra 3 and the successful completion of India’s first telesurgery trial, we reaffirm our commitment to driving advanced innovation and accessibility in robotic surgeries.”
  • Dr. Fredric Moll, Vice Chairman, SS Innovations: “I extend my heartfelt congratulations to Dr. Srivastava and the entire SSI team. The Mantra 3 system broadens the reach of surgeons and enhances their efficiency. I am excited to contribute to this cutting-edge robotic system.”
  • Dr. Mylswamy Annaduari, Ex-Director, ISRO Satellite Centre: “The launch of SSI Mantra 3 signifies the future of Indian medical innovation. This system will elevate the Indian healthcare system to the forefront globally.”
  • Dr. Naresh Trehan, Chairman & Managing Director of Medanta, The Medcity: “The rapid development of the Mantra 3 is a testament to Dr. Srivastava’s dedication and vision. We eagerly look forward to incorporating the Mantra 3 system in our hospitals.”
  • Dr. Devi Shetty, Founder and Chairman, Narayana Healthcare: “This is a remarkable achievement, showcasing India’s advancement in robotics. I hope Mantra becomes an essential accessory in operation theatres worldwide.”

SS Innovations is committed to revolutionizing the field of robotic surgery by making advanced surgical technologies cost-effective and accessible worldwide. With the introduction of the SSI Mantra 3 and the pioneering human telesurgery trial, the company continues to push the boundaries of medical innovation, contributing significantly to the Make in India initiative and global healthcare excellence.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related News